Morningstar Investor users sign in here.

Company Profile

  • Business description

    ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

  • Contact

    Route de la Corniche 3B
    Biopole
    Epalinges 1066
    CHE

    T: +41 216530200

    https://www.adctherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    274

Stocks News & Analysis

stocks

Market is underestimating ASX pathology shares

Morningstar sees several reasons to expect a stronger recover than market consensus.
stocks

What is next for BHP and Anglo

As the deadline for raising the bid approaches we lower our fair value estimate for BHP.
stocks

4 cheap ASX shares owned by top-rated funds

These companies could offer good value and have the stamp of approval from Morningstar Gold Medalist equity funds.

Market Movers

Name
Last price
Change
% Change
Jupiter Mines Ltd JMS 0.32 0.04 -9.86%
Sayona Mining Ltd SYA 0.04 0.01 -12.24%
Telstra Group Ltd TLS 3.57 0.10 -2.72%
The Star Entertainment Group Ltd SGR 0.50 0.04 -7.41%
South32 Ltd S32 3.90 0.01 0.26%
Imugene Ltd IMU 0.07 0.00 0.00%
Alligator Energy Ltd AGE 0.07 0.00 3.08%
Pilbara Minerals Ltd PLS 4.15 0.05 -1.19%
Red 5 Ltd RED 0.49 0.02 3.16%
Peninsula Energy Ltd PEN 0.12 0.01 -4.17%